The issue I see is that right now L will be completely additive to existing cost. That increases healthcare costs initially which is a burden many health care systems simply don’t want or perhaps can’t handle without political implications. I agree with your assessment about relative cost and even believe that replacement benefit will come into play at some time but that will require a change in SOC guidelines. Maybe this can be absorbed relatively pain free but with rising health care costs it seems like it would be a consideration especially if this platform spreads out quickly into other indications. Best wishes
Market Data 
Markets 
AI
